DOI: https://doi.org/10.22263/2312-4156.2016.1.7
Petrovich D.M.*, Kunder E.V.*, Volkova М.V.**
The relationship between spondylarthrites and inflammatory bowels diseases
*State Educational Establishment «Belarusian Medical Academy of Post-Graduate Education», Minsk, Republic of Belarus
**Educational Establishment «Vitebsk State Order of Peoples’ Friendship Medical University», Vitebsk, Republic of Belarus
Vestnik VGMU. 2016;15(1):7-18.
Abstract.
The publications of the last decade reflect the renaissance of the problem of studying the relationships between spondylarthrites and inflammatory bowels diseases. Intestinal inflammation is most often the primary process and precedes spondylarthritis. The main events of the immunopathogenesis are considered to be migration of immune cells from the lymphoid structures of the bowels to the synovial tissue, presentation of arthritogenic structures and activation of immune inflammation in the synovium. A similar spectrum of proinflammatory cytokines is involved in the pathological process.
This review presents modern data about the relationships between spondylarthrites and inflammatory bowels diseases. New possibilities of the laboratory examination of patients to prognosticate the development of inflammation in the intestines and the locomotor system, as well as to assess the inflammatory activity are discussed. The possibilities of high-tech treatment of inflammatory bowels diseases and spondylarthrites are analyzed.
Key words: spondylarthrites, inflammatory bowels diseases, autoantibodies.
References
1. Leirisalo-Repo M, Turunen U, Stenman S, Helenius P, Seppälä K. High frequency of silent inflammatory bowel disease in spondyloarthropathy. Arthritis Rheum. 1994 Jan;37(1):23-31.
2. Turkcapar N, Toruner M, Soykan I, Aydintug OT, Cetinkaya H, Duzgun N, Ozden A, Duman M. The prevalence of extraintestinal manifestations and HLA association in patients with inflammatory bowel disease. Rheumatol Int. 2006 May;26(7):663-8.
3. Mielants H, Veys EM, Cuvelier C, De Vos M, Goemaere S, De Clercq L, Schatteman L, Elewaut D. The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol. 1995 Dec;22(12):2273-8.
4. Mielants H, Veys EM, Cuvelier C, De Vos M, Goemaere S, De Clercq L, Schatteman L, Gyselbrecht L, Elewaut D. The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joints. J Rheumatol. 1995 Dec;22(12):2279-84.
5. Fantini MC, Pallone F, Monteleone G. Common immunologic mechanisvs in inflammatory bowel disease and spondyloarthropathies. World J Gastroenterol. 2009 May;15(20):472-78.
6. Münch H, Purrmann J, Reis HE, Bertrams J, Zeidler H, Stolze T, Miller B, Korsten S, Cremers J, Strohmeyer G. Clinical features of imflammatory joint and spine manifestations in Crohn’s disease. Hepatogastroenterology. 1986 Jun;33(3):123-7.
7. D'Incà R, Podswiadek M, Ferronato A, Punzi L, Salvagnini M, Sturniolo GC. Articular manifestations in inflammatory bowel disease patients: a prospective study. Dig Liver Dis. 2009 Aug;41(8):565-9.
8. Beslek A, Onen F, Birlik M, Akarsu M, Akar S, Sari I, Gurler O, Akpinar H, Manisali M, Akkoc N. Prevalence of spondyloarthritis in Turkish patients with inflammatory bowel disease. Rheumatol Int. 2009 Jun;29(8):955-7.
9. Rebelo A, Leite S, Cotter J. Association of ankylosing spondylitis and Crohn's disease successfully treated with infliximab. BioDrugs. 2010 Dec 14;24 Suppl 1:37-9.
10. Brakenhoff LK, van der Heijde DM, Hommes DW, Huizinga TW, Fidder HH. The joint-gut axis in inflammatory bowel diseases. J Crohns Colitis. 2010 Sep;4(3):257-68.
11. Li WQ, Han JL, Chan AT, Qureshi AA. Psoriasis, psoriatic arthritis and increased risk of incident Crohn’s disease in US women. Ann Rheum Dis. 2013 Jul;72(7):1200-5.
12. Vavricka SR, Brun L, Ballabeni P, Pittet V, Prinz Vavricka BM, Zeitz J, Rogler G, Schoepfer AM. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011 Jan;106(1):110-9.
13. Abraham C, Cho JH. Inflammatory bowel diseases. N Engl J Med. 2009 Nov;361(21):2066-78.
14. Cho JH. The genetics and immunopathogenesis of inflammatory bowel diseases. Nat Rev Immunol. 2008 Jun;8(6):458-66.
15. Van den Bosch F, Kruithof E, De Vos M, De Keyser F, Mielants H. Crohn’s disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet. 2000 Nov;356(9244):1821-2.
16. Rimbras M, Marinescu M, Voiosu MR. Bowel lesions in spondyloarthritides. Rom J Intern Med. 2009;47(1):75-85.
17. Campbell DJ, Butcher EC. Rapid acquisition of tissue-specific homing phenotypes by CD4(+) T cells activated in cutaneous or mucosal lymphoid tissues. J Exp Med. 2002 Jan;195(1):135-41.
18. Berlin C, Bargatze RF, Campbell JJ, von Andrian UH, Szabo MC, Hasslen SR, Nelson RD, Berg EL, Erlandsen SL, Butcher EC. Alpha 4 integrins mediate lymphocyte attachment and rolling under physiologic flow. Cell. 1995 Feb;80(3):413-22.
19. Souza HS, Elia C, Spencer J, MacDonald T. Expression of lymphocyte-endothelial receptor-ligand pairs, alpha4beta7/MadCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease. Gut. 1999 Dec;45(6):856-63.
20. Stenstad H, Ericsson A, Johansson-Lindbom B, Svensson M, Marsal J, Mack M, Picarella D, Soler D, Marquez G, Briskin M, Agace WW. Gut associated lymphoid tissue-primed CD4+ T cells display CC9-dependent and -independent homing to the small intestine. Blood. 2006 May;107(9):3447-54.
21. Salmi M, Jalkanen S. Endothelial ligands and homing of mucosal leukocytes in extraintestinal manifestations of IBD. Inflamm Bowel Dis. 1998 May;4(2):149-56.
22. Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernández-Sueiro JL, Balish E, Hammer RE. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 pransgenic rats. J Exp Med. 1994 Dec;180(6):2359-64.
23. Rath HC, Wilson KH, Sartor RB. Differential induction of colitis in HLA-B27 transgenic rats selectively colonized with Bacteroides vulgatus or Escherichia coli. Infect Immun. 1999 Jun;67(6):2969-74.
24. Mielants H, Veys EM, De Vos M, Cuvelier C, Goemaere S, De Clercq L, Schatteman L, Elewaut D. The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects. J Rheumatol. 1995 Dec;22(12):2266-72.
25. Palm O, Moum B, Ongre A, Gran JT. Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). J Rheumatol. 2002 Mar;29(3):511-5.
26. Kuon W, Sieper J. Identification of HLA-B27-restricted peptides in reactive arthritis and other spondyloarthropathies: computer algoriths and fluorescent activated cell sorting analysis as tools for hunting of HLA-B27-restricted chlamydial and autologous crossreactive peptides involved in reactive arthritis and ankylosing spondylitis. Rheum Dis Clin North Am. 2003 Aug;29(3):595-611.
27. Thiel A, Wu P, Lauster R, Braun J, Radbruch A, Sieper J. Analysis of the antigen-specific T cell response in reactive arthritis by fpow cytometry. Arthritis Rheum. 2000 Dec;43(12):2834-42.
28. Cohavy O, Bruckner D, Gordon LK, Misra R, Wei1 B, Eggena1 ME, Targan SR, Braun1 J.Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect Immun. 2000 Mar;68(3):1542-8.
29. Ramos M, Alvarez I, Sesma L, Logean A, Rognan D, López de Castro JA. Molecular mimicry of an HLA-B27-derived ligand of arthritis-linked subtypes with chlamydial proteins. J Biol Chem. 2002 Oct;277(40):37573-81.
30. Mundwiler ML, Mei L, Landers CJ, Reveille JD, Targan S, Weisman MH. Inflammatory bowel disease serologies in ankylosing spondylitis patients: a pilot study. Arthritis Res Ther. 2009;11(6):R177.
31. Fina D, Sarra M, Fantini MC, Rizzo A, Caruso R, Caprioli F, Stolfi C, Cardolini I, Dottori M, Boirivant M, Pallone F, Macdonald TT, Monteleone G. Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology. 2008 Apr;134(4):1038-48.
32. Jandus C, Bioley G, Rivals JP, Dudler J, Speiser D, Romero P. Increased number of circulating polyfunctional Th17 memory cells in patients with seronegativespondyloarthritides. Arthritis Rheum. 2008 Aug;58(8):2307-17.
33. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang H, Targan S, Datta LW, Kistner EO, Schumm LP, Lee AT, Gregersen PK, Barmada MM, Rotter JI, Nicolae DL, Cho JH. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006 Dec;314(5804):1461-3.
34. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity. 1999 Mar;10(3):387-98.
35. Armaka M, Apostolaki M, Jacques P, Kontoyiannis DL, Elewaut D, Kollias G. Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J Exp Med. 2008 Feb;205(2):331-7.
36. Van Praet L, Van den Bosch F, Mielants H, Elewaut D. Mucosal inflammation in spondylarthritides: past, present, and future. Curr Rheumatol Rep. 2011 Oct;13(5):409-15.
37. Van Praet L, Van den Bosch FE, Jacques P, Carron P, Jans L, Colman R, Glorieus E, Peeters H, Mielants H, De Vos M, Cuvelier C, Elewaut D. Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis. 2013 Mar;72(3):414-7.
38. Sandborn WJ, Stenson WF, Brynskov J, Lorenz RG, Steidle GM, Robbins JL, Kent JD, Bloom BJ. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol. 2006 Feb;4(2):203-11.
39. Mielants H. Ankylosing spondylitis and reactive arthritis: pathogenic aspects and therapeutic consequenses. Ghent: Chent University; 1988. 357 p.
40. Hascelik G, Oz B, Olmez N, Memis A, Yoruk G, Unsal B, Ekinci N. Association of macroscopic gut inflammation with disease activity, functional status and quality of life in ankylosing spondylitis. Rheumatol Int. 2009 May;29(7):755-8.
41. Gisondi P, Del Giglio M, Cozzi A, Girolomoni G. Psoriasis, the liver, and the gastrointestinal tract. Dermatol Ther. 2010 Mar-Apr;23(2):155-9.
42. Pérez Alamino R, Maldonado Cocco JA, Citera G, Arturi P, Vazquez-Mellado J, Sampaio-Barros PD, Flores D, Burgos-Vargas R, Santos H, Chavez-Corrales JE, Palleiro D, Gutierrez MA, Vieira-Sousa E, Pimentel-Santos FM, Paira S, Berman A, Moreno-Alvarez M, Collantes-Estevez E. Differential features between primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease. J Rheumatol. 2011 Aug;38(8):1656-60.
43. Sundström B, Wållberg-Jonsson S, Johansson G. Diet, disease activity, and gastrointestinal symptoms in patients with ankylosing spondylitis. Clin Rheumatol. 2011 Jan;30(1):71-6.
44. Hoffman IE, Demetter P, Peeters M, De Vos M, Mielants H, Veys EM, De Keyser F.Anti-saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy. Ann Rheum Dis. 2003 May;62(5):455-9.
45. Rimbaş M, Marinescu M, Voiosu MR. Bowel lesions in spondyloarthritides. Rom J Intern Med. 2009;47(1):75-85.
46. Török HP, Glas J, Gruber R, Brumberger V, Strasser C, Kellner H, Märker-Hermann E, Folwaczny C. Inflammatory bowel disease-specific autoantibodies in HLA-B27-associated spondyloarthropathies: increased prevalence of ASCA and pANCA. Digestion. 2004;70(1):49-54.
47. Andretta MA, Vieira TD, Nishiara R, Skare TL. Anti-Saccharomyces cerevisiae (ASCA) and anti-endomysial antibodies in spondyloarthritis. Rheumatol Int. 2012 Feb;32(2):551-4.
48. Roggenbuck D, Reinhold D, Werner L, Schierack P, Bogdanos DP, Conrad K. Glycoprotein 2 antibodies in Crohn’s disease. Adv Clin Chem. 2013;60:187-208.
49. Generini S, Giacomelli R, Fedi R, Fulminis A, Pignone A, Frieri G, Del Rosso A, Viscido A, Galletti B, Fazzi M, Tonelli F, Matucci-Cerinic M. Infliximab in spondyloarthropathy associated with Crohn’s disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis. 2004 Dec;63(12):1664-9.
50. Braun J, Baraliakos X, Listing J, Davis J, van der Heijde D, Haibel H, Rudwaleit M, Sieper J. Differences in the incidence of flares or the new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factorn alpha agents. Arthritis Rheum. 2007 May;57(4):639-47.
51. van der Heijde D, Schiff MH, Sieper J, Kivitz AJ, Wong RL, Kupper H, Dijkmans BA, Mease PJ, Davis JC Jr. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maimtained for up to 2 years: long-term results from ATLAS trial. Ann Rheum Dis. 2009 Jun;68(6):922-9.
52. van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, Dougados M, Reveille JD, Wong RL, Kupper H, Davis JC Jr. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006 Jul;54(7):2136-46.
